Patients with advanced NSCLC positive for NRG1 fusion are currently being investigated in the TAPUR clinical trial (Group 18: NRG1) (NCT02693535) for afatinib treatment. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.